Last reviewed · How we verify
NCT07154914
A Novel Insight Into CRPC Progression and Immune: Evidence From Single-cell Spatial Transcriptome Multi-omics
trial testing Abiraterone + ADT in Metastatic Hormone-Sensitive Prostate Cance in 396 participants. Not yet recruiting.
1 September 2026
Quick facts
| Lead sponsor | Anhui Medical University |
|---|---|
| Status | Not yet recruiting |
| Study type | OBSERVATIONAL |
| Enrollment | 396 |
| Start date | 1 September 2025 |
| Primary completion | 1 September 2026 |
| Estimated completion | 1 September 2026 |
Drugs / interventions tested
- Abiraterone + ADT — full drug profile →
Conditions studied
- Metastatic Hormone-Sensitive Prostate Cance — all drugs for Metastatic Hormone-Sensitive Prostate Cance →
Sponsor
Anhui Medical University
Who can join
Adults 18 to 85, male only, with Metastatic Hormone-Sensitive Prostate Cance. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study will follow patients with metastatic hormone-sensitive prostate cancer (mHSPC) who receive androgen deprivation therapy (ADT) combined with different treatments. Prostate cancer is a common cancer in men, and many patients in China are diagnosed at an advanced stage. While ADT alone has been the standard treatment, most patients eventually progress to castration-resistant disease. New medicines such as abiraterone, enzalutamide, apalutamide, darolutamide, and chemotherapy like docetaxel have shown survival benefits when added to ADT. This study aims to observe how different ADT-based combinations work in real-world practice and whether genetic differences affect outcomes. About 396 patients will be enrolled and followed until disease progression or death. The results will help identify which treatments are most effective and guide more personalized care for men with advanced prostate cancer.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07154914
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Anhui Medical University trials
Trials by the same sponsor.
- NCT07403591 — Mapsd Dual-target cTBS (Auditory Cortex and M1) for Generalized Anxiety Disorder · NA · not yet recruiting
- NCT07112612 — Minimal Residual Disease Used in Predicting Therapeutic Efficacy in Metastatic Hormone-sensitive Prostate Cancer · not yet recruiting
- NCT07112599 — Study of Predicting Lymph Node Metastasis of High-risk Prostate Cancer by Artificial Intelligence Multi-omics Analysis · recruiting
- NCT07176468 — Personalized iTBS in Real-World Clinical Settings for Schizophrenia · NA · recruiting
- NCT07486804 — Effects of taVNS Combined With tACS on Adolescents With Non-Suicidal Self-Injury · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07154914 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Anhui Medical University
- Last refreshed: 4 September 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07154914.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing